Australia's largest stock trading and investment forum Australia's #1 stock forum

BRN

Click for more information

2.44%

20.0¢ brainchip holdings ltd

2024 BrainChip Discussion, page-4203

First 4203 Last

Share
Profile

Follow
MarketingMan

5,726 Posts.

3318

16/04/24

14:47

Post #: 73369388
Share

Originally posted by Fact Finder: ↑

In the above post I have simply attempted to point out that the author of the article concerned in stating that ""We also see companies like BrainChip using digital olfactory detection to detect bacteria in blood samples. It is likely that the more olfactory chips become sensitive and able to detect dozens or hundreds of compounds at once, the more such discoveries could be used for diagnosis, not just of cancer but of many other diseases, especially metabolic diseases. Contrary to the current version, it could maybe achieve this only from the smell of our skin or breath, not even needing a blood sample." appears not to be aware of the facts that "the smell of our skin or breath" has already been proven to be a reliable method for the diagnosis of disease using sensors developed by Technion & Nanose. Indeed if you go back to 2022 I posted a link to over 900 research papers which proved the validity of using Volatile Organic Compounds in breath to diagnose a huge number of diseases.

This is nothing more and nothing less than proven Science.

What also is proven science is that Brainchip's AKIDA technology in the form of a $US25.00 AKD1000 chip can be used to analyse the output of sensors used to measure these compounds making possible handheld medical diagnostic devices that can be used in the field unconnected to the cloud.

Those who deny the science have nothing at all to add of any value.

My opinion only DYOR
Fact Finder
"BrainChip Inc. and NaNose Medical Successfully Detect COVID-19 in Exhaled Breath with Fast High-Accuracy Results
Aliso Viejo, California–February 24, 2021–BrainChip Holdings Ltd(ASX:BRN), a leading provider of ultra-low power high performance artificial intelligence technology, today announced progress in testing with theNaNose(Nano Artificial Nose) where patients’ exhaled breath samples were tested for COVID-19.
NaNose Medical technology, based on the artificial nose developed at the Technion Israel Institute of Technology, has the same sensitivity to minute quantities of Volatile Organic Compounds (VOCs) as a dog’s nose. It has been tested by the Technion since 2017 to identify diseases including Parkinson’s, cancers, kidney failure, multiple sclerosis and infectious diseases such as COVID-19. NaNose Medical collected samples from 130 patients and sent nanomaterial sensor data to BrainChip’s Research Institute in Perth, Western Australia, which configured and trained its Akida™ neuromorphic processor to interpret the data using AI/ML. The system detected the instances of COVID-19 between a disease group and a healthy control group and Akida learned to recognize patterns of VOC biomarkers associated with an infection within seconds with a high level of accuracy in a minimal time frame. NaNose Medical is currently collecting samples from three primary worldwide locations and will work with BrainChip to evaluate the data.
Astudy in Chinaconfirmed that breath sensor data is more accurate than the reverse transcription polymerase chain reaction (RT-PCR) test typically used. Accurate testing is key at early stages, even before symptoms manifest, and after treatment before patients are discharged into their communities.
Using the NaNose Medical sensor array to collect the data, and Akida to perform the diagnosis, can have a higher rate of reliability than current testing methods and poses less risk to medical professionals because no saliva or mucus samples are collected. COVID-19 is known to be spread through respiratory droplets, and more recently has beenconfirmed to be airborne.
Because Akida’s “Edge AI” is a complete neural processor that does not require an external CPU, memory, or Deep Learning Accelerator (DLA), and because it is ultra-low power, it offers a realistic opportunity for an inexpensive hand-held diagnostic testing tool akin to a breathalyzer.
“Artificial intelligence in medicine and healthcare is an emerging field and one in which we are eager to contribute with our edge AI processing solution at the Edge, for the benefit of science and humanity,” said Louis DiNardo, BrainChip CEO. Both Louis DiNardo, Brainchip CEO and Orit Marom Albeck, NaNose Medical CEO said: “Using the NaNose Medical artificial nose, and Akida’s artificial brain, is a potential breakthrough in accurate, fast, inexpensive, widespread testing with the potential to control outbreaks and reduce this disease’s death toll.”
AI/ML is transformational in medical and healthcare, from bioscience research and pathology to primary care. Akida neuromorphic computing and advanced neural networking processors support new and evolving uses such as identifying disease markers in blood or breath, detecting abnormalities in X-rays, CT scans, and MRIs, cancer diagnostics, device/sensor data, and more.
Akida brings artificial intelligence to the edge in a way that existing technologies are not capable of. The solution is high-performance, small, ultra-low power and enables a wide array of edge capabilities. The Akida Neuromorphic System-on-Chip, licensable IP, and Akida Development Environment machine learning framework are targeted for applications and devices including Smart Home, Smart City, Smart Healthcare and Smart Transportation."

Expand

Broad spectrum breath testing - hand-held medical diagnostics
They is also mention of olfactory signal processing (smell) suggesting use for devices that can identify the presence of molecules in air. Such "bloodhound" devices could be deployed for advanced medical diagnostics that could identify an extraordinary range of diseases and medical conditions simply through sampling a person's breath.

The impact on the medical diagnostics industry could be, er - breath taking.
On 23 July 2020 the company announced that Nobel Prize Laureate Professor Barry Marshall has joined Brainchip's scientific advisory board. Prof. Marshall was awarded the Nobel Prize in 2005 for his pioneering work in the discovery of the bacterium Helicobacter pylori and its role in gastritis and peptic ulcer disease. The gold-standard test for Helicobacter pylori involves analysing a person's breath.

Detection of endogenous (originating from within a person, animal or organism) volatile organic compounds resulting from various disease states has been one of the primary diagnostic tools used by physicians since the days of Hippocrates.

With the advent of blood testing, biopsies, X-rays, and CT scans the use of breath to detect medical problems fell out of clinical practice.
The modern era of breath testing commenced in 1971, when Nobel Prize winner Linus Pauling demonstrated that human breath is complex, containing well over 200 different volatile organic compounds.

Certainly works for Police breath testing to measure blood alcohol levels.

Sensing and quantifying the presence of organic compounds (and other molecules) using electronic olfactory sensors feeding into an AI processing system could be the basis for low-cost immediate medical diagnostics assisting clinicians to more quickly identify conditions warranting further investigation and providing earlier indications long before symptoms are apparent.

Semico published an article in their March, 2021 IPI Newsletter detailing a press release between NaNose (Nano Artificial Nose) Medical and BrainChip announcing a new system for electronic breath diagnosis of COVID-19. This system used an artificially intelligent nano-array based on molecularly modified gold nano particles and a random network of single-walled carbon nanotubes paired with the Akida neuromorphic AI processor from BrainChip.

Since then, NaNose has broadened the spectrum of diseases that can be detected and is working toward commercial release...

Source article: https://jwpm.com.au/industrial-marketing-blog/brn-brainchip-neuromorphic

Last edited by MarketingMan: 16/04/24

BRN Price at posting: 31.5¢ Sentiment: Buy Disclosure: Held
27 Upvote

5 Great analysis

Reply

Top Stories

GED

Golden Deeps eyes prospective Cu-Au tenements in NSW with HOA

SKS

SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne

ASX Market Open: US inflation hits 3%; local futures indicate fresh all-time-high | 12 July 2024

I88

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

TLX

Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug

There are more pages in this discussion • 2,611 more messages in this thread...

First 4203 Last

Add BRN (ASX) to my watchlist

(20min delay)
Last 20.0¢		Change -0.005(2.44%)		Mkt cap ! $371.1M

Open	High	Low	Value	Volume
20.0¢	20.5¢	19.5¢	$579.8K	2.902M

Buyers (Bids)

No.	Vol.	Price($)
37	1243524	19.5¢

Sellers (Offers)

Price($)	Vol.	No.
20.0¢	349262	10

View Market Depth

No.	Vol.	Price($)
2	2820	0.205
11	140971	0.200
40	1662303	0.195
58	1645741	0.190
33	1308037	0.185

Price($)	Vol.	No.
0.175	4902	3
0.180	137319	1
0.195	96833	7
0.200	335765	11
0.205	1040907	23

Last trade - 16.10pm 11/07/2024 (20 minute delay)

BRN (ASX) Chart